It was only a matter of time until the GLP-1 receptor agonist drugs like Ozempic and Wegovy were superseded, and now it looks ...

Weight loss clinics, telehealth companies, physicians, and pharmacies that have been prescribing or dispensing compounded GLP ...

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

First, Novo Nordisk is expanding its program to sell Wegovy GLP-1 weight loss drugs at discounted prices. Second, Novo is ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

Eli Lilly and Company (NYSE:LLY) offers a quarterly dividend of $1.50 per share and has a dividend yield of 0.71%, as of March 20. It is one of the best dividend stocks on our list as the company has ...

Novo Nordisk agreed to pay up to $2 billion for the rights to a developmental weight-loss and obesity drug from Chinese pharmaceutical company the United Bio-Technology (Hengqin) Co., as it looks to ...

A United States Senator has disclosed a series of stock trades, some raising questions about possible insider information use ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

We recently published a list of 8 Best Robinhood Stocks to Buy According to Analysts. In this article, we are going to take a ...

Eli Lilly has launched Mounjaro (Tirzepatide) in India, being the first top pharma major to bring out a GLP-1/GIP dual-action weight-loss and diabetes drug into the country.

The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...